급여불인정불인정 대상모두하나만제한선행 치료평가·계속진단·검사수치서류필수 택일
허가사항 범위 내에서 아래와 같은 기준으로 투여 시 요양급여를 인정함.
- 아 래 -
가.간헐성 파행을 동반한 만성동맥폐색증(버거씨병, 폐색성 동맥경화증, 당뇨병성 말초혈관병증 등)
*시행일: 2014.12.1.
*관련근거:
·Harrison's Principles of Internal Medicine, 18e. Chapter 249 Vascular Diseases of the Extremities
·Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e
·Goldman's Cecil Medicine , 24th Edition. Chapter 79 Atherosclerotic Peripheral Arterial Disease
·Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 9th ed. Chapter 61 Peripheral Arterial Diseases
·Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations), 2013.
·Antithrombotic Therapy in Peripheral Artery Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed, 2012.
·Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). 2007.
·Stevens JW et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-8.
·Squires H et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210.
·Pande RL et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010 Jun;15(3):181-8.
·Robless P et al. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008 Jan 23;(1)
·Hashiguchi M et al. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi. 2004 Jun;124(6):321-32.
·Hiatt WR et al. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008 Feb;47(2):330-336.